These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 4514335)

  • 1. Administration of amandine to patients on optimum L-dopa dosage.
    Fehling C
    Acta Neurol Scand Suppl; 1972; 51():119-20. PubMed ID: 4514335
    [No Abstract]   [Full Text] [Related]  

  • 2. [Principles for amantadine therapy in parkinsonism].
    Gilland O
    Lakartidningen; 1972 Nov; 69(46):5343-5. PubMed ID: 4650743
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined L-dopa and amantadine in Parkinsonism.
    Pollock M; Jorgensen PB
    Aust N Z J Med; 1972 Aug; 2(3):252-5. PubMed ID: 4564049
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of adding amantadine to optimum L-dopa dosage in Parkinson's syndrome.
    Fehling C
    Acta Neurol Scand; 1973; 49(2):245-51. PubMed ID: 4577929
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined treatment of parkinsonism with L-dopa and amantadine.
    Godwin-Austen RB; Frears CC; Bergmann S; Parkes JD; Knill-Jones RP
    Lancet; 1970 Aug; 2(7669):383-5. PubMed ID: 4194690
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of Parkinson's disease with amantadine and L-Dopa.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1972; 7(4):228-40. PubMed ID: 4556618
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of Parkinson's disease with amantadine].
    Sigwald J; Raymondeaud C; Grégoire J
    Therapeutique; 1972 Nov; 48(9):555-60. PubMed ID: 4568230
    [No Abstract]   [Full Text] [Related]  

  • 8. [Comparative value of L-dopa, amantadine, anticholinergics, and their combinations in parkinsonian syndromes].
    Ciuca I; Bulandra R; Serbanesco A; Ninosu N
    Rev Neurol (Paris); 1972 Aug; 127(2):305-8. PubMed ID: 4672049
    [No Abstract]   [Full Text] [Related]  

  • 9. Amantadine versus L-2 dopa and amatadine plus L-dopa.
    Fieschi C; Nardini M; Casacchia M; Tedone ME; Reitano M; Robotti E
    Lancet; 1970 Jul; 2(7664):154-5. PubMed ID: 4194541
    [No Abstract]   [Full Text] [Related]  

  • 10. [Amantadine therapy in parkinsonism].
    Pakkenberg H
    Ugeskr Laeger; 1973 Jan; 135(3):135-6. PubMed ID: 4685048
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical evaluation of amantadine therapy for parkinsonism and the side effects--in cases of thalamic surgery and L-dopa therapy.
    Matsumoto K; Omoto T; Beck H
    Folia Psychiatr Neurol Jpn; 1974 Jan; 28(1):1-10. PubMed ID: 4406943
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined treatment of Parkinson's disease with amantadine and L-dopa.
    Scotti G
    Lancet; 1970 Jun; 1(7661):1394-5. PubMed ID: 4194144
    [No Abstract]   [Full Text] [Related]  

  • 13. L-dopa and amantadine for Parkinsonism.
    Drug Ther Bull; 1970 Aug; 8(17):65-7. PubMed ID: 5480244
    [No Abstract]   [Full Text] [Related]  

  • 14. Amantadine HCL (Symmetrel) and its relation to Levo-Dopa in the treatment of Parkinson's disease.
    Schwab RS; England AC
    Trans Am Neurol Assoc; 1969; 94():85-90. PubMed ID: 4907453
    [No Abstract]   [Full Text] [Related]  

  • 15. [Drug therapy of Parkinson's disease with amantadine and levodopa].
    Fieschi C; Nardini M; Casacchia M; Reitano M; Tedone ME; Ferrari P; Robotti E
    Sist Nerv; 1970; 22(2):126-43. PubMed ID: 5504552
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of amantadine, placebo, and levodopa in Parkinson's disease.
    Bauer RB; McHenry JT
    Neurology; 1974 Aug; 24(8):715-20. PubMed ID: 4858417
    [No Abstract]   [Full Text] [Related]  

  • 17. [Action of amantadine HCl alone and in combination with L-dopa on parkinsonism].
    Danielczyk W; Korten JJ
    Med Monatsschr; 1971 Oct; 25(10):472-9. PubMed ID: 5122447
    [No Abstract]   [Full Text] [Related]  

  • 18. Interactions of L-dopa and amantadine in patients with Parkinsonism.
    Cox B; Danta G; Schnieden H; Yuill GM
    J Neurol Neurosurg Psychiatry; 1973 Jun; 36(3):354-61. PubMed ID: 4714097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-dopa level in plasma, primary condition for the kinetic effect.
    Birkmayer W; Danielcyk W; Neumayer E; Riederer P
    J Neural Transm; 1973; 34(2):133-43. PubMed ID: 4722571
    [No Abstract]   [Full Text] [Related]  

  • 20. Action of L-dopa, norepinephrine and amantadine on ulcers caused by reserpine in the rat.
    Gaetani M; Debeus R
    Digestion; 1972; 7(5):302-11. PubMed ID: 4671521
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.